TCRX
Tscan Therapeutics Inc
0.349$
-4.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.6% | -11.5% | +55.7% | -7.2% | +6.6% | -10.3% | -10.3% | -12.2% | -12.8% | -11.7% | -15.1% | |
| – | -10.7% | -15.2% | +81.8% | -8.5% | +6.8% | -12.9% | -13.2% | -14.9% | -16.5% | -15.5% | -21.4% | |
| – | -14.1% | +5.4% | +72.3% | -45.0% | +34.2% | -13.8% | +9.9% | +0.1% | -10.1% | -16.0% | -21.8% | |
| – | -10.9% | -15.2% | +82.9% | -8.9% | +7.0% | -13.2% | -13.4% | -15.4% | -17.4% | -16.0% | -21.8% | |
| – | -0.9% | -2.8% | +1.5% | -0.6% | +9.4% | -5.9% | -0.5% | -3.0% | -10.6% | -0.6% | -2.5% | |
| – | -10.0% | +5.6% | +22.5% | -25.7% | +25.5% | -17.1% | +5.1% | -6.7% | -36.0% | +6.8% | +55.1% | |
| – | +20.2% | +53.7% | +73.3% | -77.8% | +17.2% | +8.8% | +26.5% | +9.8% | +3.8% | +3.8% | +161.1% | |
| – | -25.7% | -10.6% | +46.5% | +17.3% | +17.3% | +16.1% | -8.6% | +40.0% | -80.5% | +85.6% | +35.6% | |
| – | -7.4% | -12.2% | -14.2% | +52.4% | +4.6% | +0.3% | +0.4% | +0.4% | +0.4% | +0.4% | -35.5% | |
| – | -10.7% | -18.5% | +107.6% | -10.2% | +5.2% | -12.8% | -15.9% | -18.5% | -14.5% | -21.3% | -28.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +19.6% | +4.7% | +1.8% | +7.4% | +0.0% | +0.1% | +0.0% | +0.0% | +0.0% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.